03/2015. Mucosal adjuvants
A review on recent patents in mucosal adjuvants has been published in the journal Recent Patents on Inflammation & Allergy Drug Discovery.
Mucosal surfaces are the major entrance for infectious pathogens and therefore mucosal immune responses serve as a first line of defence. However antiinfectious mucosal vaccines have to overcome the natural tolerance of these tissues. Mucosal vaccines require antigens with high immunogenicity and/or mucosal adjuvants to improve their immune response. This review focuses on recent developments of mucosal adyuvants published to be patented during the last year.
